Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-26366821 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
| Arm | Type | Description |
|---|---|---|
| Cohort1: JNJ-2636682/Placebo | EXPERIMENTAL | Participants will receive single dose of JNJ-26366821 or placebo on Day 1. |
| Cohort 2: JNJ-26366821/Placebo | EXPERIMENTAL | Participants will receive single dose of JNJ-26366821 or placebo on Day 1. |
| Cohort 3: JNJ-26366821/Placebo | EXPERIMENTAL | Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2. |
| Name | Type | Description |
|---|---|---|
| JNJ-26366821 | DRUG | Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC). |
| Placebo | DRUG | Participants will receive sodium chloride injection as placebo on Day 1. |
Inclusion Criteria: * Overall good health, on the basis of full physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening * Body weight 50 - 100 kilogram (kg), body mass index (BMI) 18 - 30 kilogram per meter square (kg/m\^2), inclusive at screen...
JNJ-26366821 is an investigational small molecule being developed by Johnson & Johnson. It has been studied in a Phase 1 clinical trial in healthy adult participants, and its therapeutic indications have not been disclosed. It is not an approved medicine and remains in early clinical development.
JNJ-26366821 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 study of the compound conducted in the United States.
JNJ-26366821 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The compound is investigational and has not been approved by the FDA for any indication.
JNJ-26366821 has been evaluated in one clinical trial, NCT03990519, titled A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants. The Phase 1 study was completed, enrolled 33 healthy adult participants in the United States, and used a randomized, double-blind, controlled design.
JNJ-26366821 was administered as a single subcutaneous dose in its completed Phase 1 study, NCT03990519, which evaluated the compound in healthy participants. The trial enrolled 33 participants and was randomized, double-blind, and controlled.